STRM.BIO is a biotechnology company developing a non-viral, cell-derived delivery modality that enables safe, targeted, and scalable in vivo delivery of genetic medicines. Its megakaryocyte-derived vesicle (MV) platform is designed to address the limitations of traditional viral and synthetic delivery systems, unlocking new therapeutic opportunities across gene editing, RNA therapeutics, and immune cell engineering. STRM.BIO is headquartered in Cambridge, Massachusetts.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/07/26 | $8,000,000 | Seed 2 |
Blue Bay Ventures Boehringer Ingelheim Venture Fund Delos Capital Recordati | undisclosed |
